Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.00 (0.00%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £91.78m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

Suspension - Faron Pharmaceuticals Oy

30 Mar 2026 07:30

RNS Number : 5226Y
AIM
30 March 2026
 

NOTICE

 

30/03/2026 7:30am

 

TEMPORARY SUSPENSION OF TRADING ON AIM

 

FARON PHARMACEUTICALS OY

 

At the request of the Company, trading on AIM for the under-mentioned securities was temporarily suspended from 30/03/2026 7:30am, pending an announcement.

 

SUBSCRIPTION RIGHTS, NIL PAID (DI)

(BS84X55) (FI4000602313)

If you have any queries relating to the above, please contact the Company's nominated adviser on +44 (0) 207 213 0880.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
EXCJRMRTMTJTBIF
Date   Source Headline
7th Mar 20227:00 amRNSNotice of 2021 Full-Year Results and Annual Report
4th Mar 20227:00 amRNSFaron presents at upcoming conferences
28th Feb 20225:45 pmRNSFaron Board Issues Warrants to IPF Partners
28th Feb 20227:00 amRNSFaron Obtains Debt Funding from IPF Partners
23rd Feb 20227:00 amRNSFaron Updates on Bexmarilimab Development Program
14th Feb 20227:00 amRNSFaron Announces R&D Day
3rd Feb 202210:40 amRNSScientific Reports Publishes INFORAAA Results
31st Jan 20221:30 pmRNSHoldings in Company
31st Jan 20227:00 amRNSJuho Jalkanen Appointed Chief Operating Officer
28th Jan 20227:00 amRNSGrant of options
24th Jan 20227:00 amRNSFaron at Proactive One2One Investor Forum
17th Jan 20227:00 amRNSFaron to Present at Redeye Fight Cancer Seminar
5th Jan 20227:00 amRNSFaron to Present at H.C. Wainwright BioConnect
4th Jan 20227:00 amRNSFaron Appoints Marie-Louise Fjällskog as CMO
21st Dec 20217:00 amRNSFaron’s financial calendar for 2022
9th Dec 20217:00 amRNSFaron Announces Topline MATINS Biomarker Analysis
1st Dec 20217:00 amRNSChange in Faron’s Management Team
16th Nov 20217:00 amRNSFaron to Present at Jefferies Conference 2021
9th Nov 20217:00 amRNSFaron awarded EUR 3.8 Million in Arbitration Case
3rd Nov 20213:55 pmRNSCellular and Molecular Life Sciences Publication
7th Oct 20217:00 amRNSExercise of options
5th Oct 202111:30 amRNSHolding(s) in Company
1st Oct 20212:00 pmRNSRegistration of Placing Shares with Trade Register
1st Oct 20217:00 amRNSResults of Placing and Issue Price
30th Sep 20214:31 pmRNSProposed Issue and Placing of Shares
17th Sep 20217:00 amRNSPresentation of Updated MATINS Data at ESMO
9th Sep 20217:00 amRNSFaron Announces Presentation at ESMO Congress
7th Sep 20217:00 amRNSFaron to Present at H.C. Wainwright Conference
26th Aug 20217:00 amRNSHalf-Year Financials, January 1 – June 30 2021
25th Aug 20217:00 amRNSFirst Patient Dosed in Phase II/III COVID-19 Trial
28th Jul 20217:00 amRNSNotice of Half-Year Report
12th Jul 20217:00 amRNSFaron to Host KOL Webinar on Clever-1 Receptor
22nd Jun 20217:00 amRNSUpdated corporate presentation
14th Jun 202111:05 amRNSSecond Price Monitoring Extn
14th Jun 202111:00 amRNSPrice Monitoring Extension
14th Jun 20217:00 amRNSBexmarilimab granted key US patent
3rd Jun 20217:00 amRNSBexmarilimab results published in CCR
17th May 20217:00 amRNSBexmarilimab shows promising anti-tumour activity
14th May 20217:00 amRNSUS rights to patent related to Traumakine
10th May 20212:30 pmRNSHolding(s) in Company
29th Apr 202112:45 pmRNSGrant of options
23rd Apr 20211:45 pmRNSBoard Change
23rd Apr 20211:45 pmRNSResult of AGM
29th Mar 20217:00 amRNSAppointment of a Broker
25th Mar 20217:45 amRNSExercise of Options
25th Mar 20217:30 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20217:15 amRNSFaron´s Annual Report 2020 published
25th Mar 20217:00 amRNSFinancial statement January 1 to December 31 2020
22nd Mar 20217:00 amRNSBexmarilimab (Clevegen) development update
11th Mar 20217:00 amRNSFaron to Present at Oppenheimer Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.